Scientific Advisory Board
Scientific Advisory Board
Dr. Grint was most recently CEO and a member of the board of directors of AmpliPhi Biosciences which recently merged with C3J Therapeutics to form Armata Pharmaceuticals. Dr. Grint has more than two decades of experience in biologics and small molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology and oncology therapeutic areas. Dr. Grint has also served in senior management roles at Cerexa, Forest Laboratories, Kalypsys, Pfizer, IDEC Pharmaceuticals and Schering-Plough Corporation. He is currently a Board member at Amplyx Pharmaceuticals and Synedgen. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and holds a Bachelor’s degree from St. Mary’s Hospital College, University of London and a medical degree from St. Bartholomew’s Hospital College, University of London.
Prof. Andrew Scott is Laboratory Head at the Olivia Newton-John Cancer Research Institute; Director, Department of Molecular Imaging and Therapy, Austin Health; and Professor, University of Melbourne, La Trobe University, and Monash University. His clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer with monoclonal antibodies, and in molecular imaging particularly oncology applications in PET in staging cancer. His laboratory has been involved in the preclinical development and first-in-man trials of numerous recombinant antibodies in cancer patients, and five antibodies developed in his laboratory have been licenced to Biotech and Pharma companies. He has served on numerous Government and International advisory committees, not-for-profit Boards, and journal Editorial Boards. Prof. Scott has published 340 peer reviewed papers and 22 book chapters, principally in the areas of oncology and molecular imaging.
John Hazle, Ph.D. is Professor and Chair of the Department of Imaging Physics at one of the world’s largest cancer research and treatment centers. In his role on the Imagion Biosystems’ Board of Directors, John represents the interests and professional requirements of an uncompromising customer who buys and uses advanced diagnostic
instrumentation on a daily basis. Dr. Hazle is a medical physicist with over 25 years of experience. He is board-certified and licensed in Texas for both therapeutic and diagnostic medical physics. His research interests include image-guided therapy, pre- clinical imaging, and novel early detection technologies. Dr. Hazle is highly sought-after as an academic and business collaborator, and he serves on multiple institutional committees, engages as a medical imaging expert with industry partners, and is a reviewer for six peer-reviewed scientific journals. Dr. Hazle holds the Barnard W. Biedenharn Chair in Cancer Research and has a faculty appointment with the University of Texas Graduate School of Biomedical Sciences. Following Bachelor’s and Master’s degree studies at the University of Kentucky, Dr. Hazle earned his PhD degree in Biophysics from the University of Texas Health Science Center at Houston.
Prof Lisa Horvath is the Director, Department of Medical Oncology, and inaugural Director of Research at the Chris O’Brien Lifehouse. She is also the Professor of Medical Oncology (Genitourinary cancer) at the University of Sydney and Head of Clinical Prostate Cancer Research at the Garvan Institute for Medical Research. She has an active clinical practice and is involved with a large number of clinical trials in prostate and colorectal cancers in addition to phase I trial work.
Having completed medical school at the University of Sydney and trained in medical oncology at Royal Prince Alfred Hospital she subsequently worked at the Garvan Institute completing her PhD in translational research in 2004. She has published >100 original research papers published in peer-reviewed journals in the last 19 years across the fields of cancer biology, biomarkers and clinical trials.
Dr. Ivkov’s research focuses on the development and characterization of magnetic nanoparticles and AMF-devices for cancer therapy. Upon his arrival to the Department of Radiation Oncology and Molecular Radiation Sciences at The Johns Hopkins University School of Medicine in early 2008, Dr. Ivkov began a broad research program with the aim to develop clinical applications of heat-based therapies for metastatic cancer. A significant aspect of this research interest is the development and characterization of nanoparticle formulations and magnetic coil components that produce therapeutic heat in animal models of human cancer, particularly when combined with other therapeutic agents. The nature of this research is multi-disciplinary and translational, and thus requires a diverse research team comprising multiple skills. His M.Sc. project was theoretical and fundamental focusing on understanding the nature of colloid stability. Magnetic nanoparticle suspensions are colloids and his early theoretical research, post-doctoral training, and ongoing collaborative research with scientists at the National Institute of Standards and Technology (NIST) provides access to unique tools and insight into the physical and biological implications of these systems. His Ph.D. research focused on the thermodynamic properties of actin polymerization as a reversible higher order phase transition. To complete the work he developed expertise in the methods needed to isolate, purify, and characterize proteins, and he gained an appreciation for the implications of heat in biological systems. His experience in the private sector is more directly related to the translational aspects of his current research. After leaving NIST, he co-founded Triton BioSystems, Inc. in 2002 to develop targeted nanoparticle therapeutic agents for the treatment of local cancer. At Triton, Dr. Ivkov led product development efforts directed to targeted magnetic nanoparticle and devices for local ablative thermal therapy of cancer. He developed a magnetic iron oxide nanoparticle construct that is now commercially available for research, and that has been used in canine clinical trials of cancer. He has published over eighty scientific papers and patents (issued and pending) in nanotechnology, nanobiotechnology, magnetic devices, colloid and interface science, neutron scattering, and targeted therapy. He currently serves as Editor-in-Chief of Convergent Science Physical Oncology, and he has been a member of the International Journal of Hyperthermia Editorial Board since 2012.